-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This article is original by Translational Medicine Network.
Please indicate the source for reprinting.
Author: Daisy Guide: Recently, two articles published in New England Journal of Medicine showed that-six months after the second dose of BNT162b2 vaccine, the antibody concentration was significant Decrease, especially in men, people 65 years of age or older, and immunosuppressed people
.
As well as observing the effectiveness of the BNT162b2 vaccine against any serious or fatal cases of new coronavirus, the report said that in the first two months after the second injection, its peak was about 96%, and then remained at this level for six months.
Effective level
.
On October 11th, based on these two articles, the researchers once again put forward the view that "antibody levels decreased after the second injection of Pfizer, but the protective effect against serious diseases still exists" in "The BMJ"
.
A study found that six months after the second dose of Pfizer-BioNTech's new crown vaccine, the concentration of antibodies in healthcare workers dropped significantly, especially among men, people 65 years of age or older, and immunosuppressed people
.
On October 11, researchers published an article titled "Covid-19: Antibody levels fall after second Pfizer dose, but protection against severe disease remains, studies indicate" on "The BMJ"
.
According to two articles published in the "New England Journal of Medicine", it was discussed that "antibody levels decreased after the second injection of Pfizer, but the protective effect against serious diseases still exists"
.
https://doi.
org/10.
1136/bmj.
n2481 Israeli researchers conducted a six-month longitudinal prospective study, and carried out antibody tests on approximately 4,000 vaccinated medical staff every month
.
At 6 months, a mixed model analysis showed that compared with participants aged 18-45, participants aged 65 years or older had reduced IgG antibody and neutralizing antibody concentrations by 38% and 42%, respectively
.
Compared with women in the same age group, men 65 years of age or older also experienced a decrease of 37% (IgG) and 46% (neutralization)
.
The distribution of antibodies 6 months after receiving the second dose of the BNT162b2 vaccine.
This study published in the New England Journal of Medicine reported that immunosuppressed participants had lower antibody concentrations compared to non-immunosuppressed participants Participants with a BMI of 30 or above had a 31% higher concentration of neutralizing antibodies, compared with those with a BMI of less than 30
.
Researchers published an article titled "Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months"
.
doi:10.
1056/NEJMoa2114583 Researchers said that the IgG antibody concentration dropped at a consistent rate, while the neutralizing antibody concentration dropped rapidly in the first three months after the second injection, and then slowly dropped between three to six months
.
They pointed out that compared with other vaccines (such as measles, mumps and rubella vaccines), the decrease in antibody concentration after Pfizer's new crown vaccine is more significant and rapid
.
The limitations of this study include that it only involves most healthy healthcare workers, so it may not be representative of the wider population
.
In addition, it did not study cases of the new coronavirus, only the level of antibodies
.
Another study on durable protection against severe diseases was also published in "New England Journal of Medicine".
Researchers published an article entitled "Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar".
The effectiveness of the BNT162b2 vaccine in Qatar against SARS-CoV-2 infection and disease
.
doi: 10.
1056/NEJMoa2114114 These researchers found that in the first month after the second injection, the effectiveness reached 78%, and then gradually decreased.
After the fourth month, the rate of decline accelerated, reaching the fifth to seventh month.
20%
.
However, the researchers observed the effectiveness against any serious or fatal cases of the new coronavirus.
They reported that in the first two months after the second injection, the peak was about 96%, and then it remained at the same level for six months.
This level
.
To carry out this study, the researchers matched people with positive PCR results with those with negative PCR based on gender, 10-year-old age group, nationality, the reason for PCR testing, and the calendar week of PCR testing
.
Using the national COVID-19 database, they studied cases between January 1 and September 5, 2021
.
In subjects who received one dose of Pfizer vaccine, a total of 8,203 breakthrough infections were recorded, and in subjects who received two doses of vaccine, 10543 infections were recorded
.
The researchers concluded that although the overall protection against infection weakened rapidly one month after the second injection, the protection against hospitalization and death “maintained at a strong level for at least six months after the second injection.
Level"
.
The paper acknowledges some limitations, including the lack of personal data about pre-existing diseases, only a small part of the study population may have severe coexisting diseases, and only 9% of the population are over 50 years old
.
Therefore, this finding cannot be generalized to other countries where the elderly constitute a large proportion of the total population
.
Reference materials: https:// Note: This article aims to introduce the progress of medical research and cannot be used as a reference for treatment options
.
If you need health guidance, please go to a regular hospital
.
Popular·Article Diagnostic Test [The Lancet] Call for action! Nearly half of the world's people cannot get basic diagnosis for many common diseases.
Can the COVID-19 pandemic help change the diagnosis? Immunotherapy [Nature Sub-Journal] Lung epithelial cells control lung immunity? This will lay the foundation for the treatment of many lung diseases! Tumor Research 【Research】Be alert! Summarizing 30 years of big data: esophageal adenocarcinoma is showing a younger trend.
Medical trends [News] The Nobel Prize in Physiology or Medicine in 2021 was announced, and the pain receptors won! Intestinal health [PNAS] research has discovered the "second brain" that exists in the intestine, and its glial will open up new ways to treat intestinal diseases! Tumor Research [Nature Sub-Journal] The use of single-cell multi-omics to study tumor cells is a new idea, the Harvard Medical School and other top-level teams have created a precedent! Tumor research [Science] protein may become a new breakthrough in cancer treatment! New Coronavirus [Science] The truth about the source of SARS-CoV-2? The coronavirus that is the closest to the new coronavirus so far has been found in Lao bats, with a matching rate of 96.
8%! Coronavirus [The BMJ] In Israel, where the vaccination rate is 78%, why is the epidemic still out of control? Is there a need to worry about the effectiveness of the new crown vaccine? Is it necessary to strengthen the injection? Organoid Research [Nature Sub-Journal] A 3D pancreatic cancer tumor model cultivated by an international team of scientists including Shanghai Jiaotong University can effectively improve the treatment of pancreatic cancer.
Tumor Research [Science Sub-Journal] Salt has the effect of inhibiting tumors ? Scientists explain unexpected discoveries for you through mouse experiments! Recommendation·Activity The 5th Symposium on Modern Clinical Molecular Diagnosis at the 3rd Shanghai International Cancer Conference
Please indicate the source for reprinting.
Author: Daisy Guide: Recently, two articles published in New England Journal of Medicine showed that-six months after the second dose of BNT162b2 vaccine, the antibody concentration was significant Decrease, especially in men, people 65 years of age or older, and immunosuppressed people
.
As well as observing the effectiveness of the BNT162b2 vaccine against any serious or fatal cases of new coronavirus, the report said that in the first two months after the second injection, its peak was about 96%, and then remained at this level for six months.
Effective level
.
On October 11th, based on these two articles, the researchers once again put forward the view that "antibody levels decreased after the second injection of Pfizer, but the protective effect against serious diseases still exists" in "The BMJ"
.
A study found that six months after the second dose of Pfizer-BioNTech's new crown vaccine, the concentration of antibodies in healthcare workers dropped significantly, especially among men, people 65 years of age or older, and immunosuppressed people
.
On October 11, researchers published an article titled "Covid-19: Antibody levels fall after second Pfizer dose, but protection against severe disease remains, studies indicate" on "The BMJ"
.
According to two articles published in the "New England Journal of Medicine", it was discussed that "antibody levels decreased after the second injection of Pfizer, but the protective effect against serious diseases still exists"
.
https://doi.
org/10.
1136/bmj.
n2481 Israeli researchers conducted a six-month longitudinal prospective study, and carried out antibody tests on approximately 4,000 vaccinated medical staff every month
.
At 6 months, a mixed model analysis showed that compared with participants aged 18-45, participants aged 65 years or older had reduced IgG antibody and neutralizing antibody concentrations by 38% and 42%, respectively
.
Compared with women in the same age group, men 65 years of age or older also experienced a decrease of 37% (IgG) and 46% (neutralization)
.
The distribution of antibodies 6 months after receiving the second dose of the BNT162b2 vaccine.
This study published in the New England Journal of Medicine reported that immunosuppressed participants had lower antibody concentrations compared to non-immunosuppressed participants Participants with a BMI of 30 or above had a 31% higher concentration of neutralizing antibodies, compared with those with a BMI of less than 30
.
Researchers published an article titled "Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months"
.
doi:10.
1056/NEJMoa2114583 Researchers said that the IgG antibody concentration dropped at a consistent rate, while the neutralizing antibody concentration dropped rapidly in the first three months after the second injection, and then slowly dropped between three to six months
.
They pointed out that compared with other vaccines (such as measles, mumps and rubella vaccines), the decrease in antibody concentration after Pfizer's new crown vaccine is more significant and rapid
.
The limitations of this study include that it only involves most healthy healthcare workers, so it may not be representative of the wider population
.
In addition, it did not study cases of the new coronavirus, only the level of antibodies
.
Another study on durable protection against severe diseases was also published in "New England Journal of Medicine".
Researchers published an article entitled "Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar".
The effectiveness of the BNT162b2 vaccine in Qatar against SARS-CoV-2 infection and disease
.
doi: 10.
1056/NEJMoa2114114 These researchers found that in the first month after the second injection, the effectiveness reached 78%, and then gradually decreased.
After the fourth month, the rate of decline accelerated, reaching the fifth to seventh month.
20%
.
However, the researchers observed the effectiveness against any serious or fatal cases of the new coronavirus.
They reported that in the first two months after the second injection, the peak was about 96%, and then it remained at the same level for six months.
This level
.
To carry out this study, the researchers matched people with positive PCR results with those with negative PCR based on gender, 10-year-old age group, nationality, the reason for PCR testing, and the calendar week of PCR testing
.
Using the national COVID-19 database, they studied cases between January 1 and September 5, 2021
.
In subjects who received one dose of Pfizer vaccine, a total of 8,203 breakthrough infections were recorded, and in subjects who received two doses of vaccine, 10543 infections were recorded
.
The researchers concluded that although the overall protection against infection weakened rapidly one month after the second injection, the protection against hospitalization and death “maintained at a strong level for at least six months after the second injection.
Level"
.
The paper acknowledges some limitations, including the lack of personal data about pre-existing diseases, only a small part of the study population may have severe coexisting diseases, and only 9% of the population are over 50 years old
.
Therefore, this finding cannot be generalized to other countries where the elderly constitute a large proportion of the total population
.
Reference materials: https:// Note: This article aims to introduce the progress of medical research and cannot be used as a reference for treatment options
.
If you need health guidance, please go to a regular hospital
.
Popular·Article Diagnostic Test [The Lancet] Call for action! Nearly half of the world's people cannot get basic diagnosis for many common diseases.
Can the COVID-19 pandemic help change the diagnosis? Immunotherapy [Nature Sub-Journal] Lung epithelial cells control lung immunity? This will lay the foundation for the treatment of many lung diseases! Tumor Research 【Research】Be alert! Summarizing 30 years of big data: esophageal adenocarcinoma is showing a younger trend.
Medical trends [News] The Nobel Prize in Physiology or Medicine in 2021 was announced, and the pain receptors won! Intestinal health [PNAS] research has discovered the "second brain" that exists in the intestine, and its glial will open up new ways to treat intestinal diseases! Tumor Research [Nature Sub-Journal] The use of single-cell multi-omics to study tumor cells is a new idea, the Harvard Medical School and other top-level teams have created a precedent! Tumor research [Science] protein may become a new breakthrough in cancer treatment! New Coronavirus [Science] The truth about the source of SARS-CoV-2? The coronavirus that is the closest to the new coronavirus so far has been found in Lao bats, with a matching rate of 96.
8%! Coronavirus [The BMJ] In Israel, where the vaccination rate is 78%, why is the epidemic still out of control? Is there a need to worry about the effectiveness of the new crown vaccine? Is it necessary to strengthen the injection? Organoid Research [Nature Sub-Journal] A 3D pancreatic cancer tumor model cultivated by an international team of scientists including Shanghai Jiaotong University can effectively improve the treatment of pancreatic cancer.
Tumor Research [Science Sub-Journal] Salt has the effect of inhibiting tumors ? Scientists explain unexpected discoveries for you through mouse experiments! Recommendation·Activity The 5th Symposium on Modern Clinical Molecular Diagnosis at the 3rd Shanghai International Cancer Conference
